Director, Precision Medicine and Companion Diagnostics

Job description

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: To aid in this mission, the Translational Medicine (TM) team at RevMed is seeking a highly motivated, scientifically creative, and collaborative Director to work in a fast-paced environment within a cross-functional team. This role will be the Translational Medicine lead for precision medicine and companion diagnostic (CDx) development for RAS(ON) inhibitors across different solid cancer types. Activities will be center...